Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II study of HP-001 capsules plus dexamethasone in relapsed/refractory multiple myeloma
CTR20254042Phase 2Active
- Sponsor
- Shanghai Chaoyang Pharmaceutical
- Start
- Dec 2025
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Molecular Glues → Targeted Protein Degraders (TPDs) → Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of HP-001, dexamethasone in multiple myeloma (MM), sponsored by Shanghai Chaoyang Pharmaceutical. Started Dec 2025; status: active.
02
Drugs
HP-001dexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on CTR20254042.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20254042.